IL147455A0 - Purine derivative inhibitors of tyrosine protein kinase syk - Google Patents

Purine derivative inhibitors of tyrosine protein kinase syk

Info

Publication number
IL147455A0
IL147455A0 IL14745500A IL14745500A IL147455A0 IL 147455 A0 IL147455 A0 IL 147455A0 IL 14745500 A IL14745500 A IL 14745500A IL 14745500 A IL14745500 A IL 14745500A IL 147455 A0 IL147455 A0 IL 147455A0
Authority
IL
Israel
Prior art keywords
protein kinase
purine derivative
tyrosine protein
kinase syk
derivative inhibitors
Prior art date
Application number
IL14745500A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL147455A0 publication Critical patent/IL147455A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
IL14745500A 1999-07-30 2000-07-28 Purine derivative inhibitors of tyrosine protein kinase syk IL147455A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918035.8A GB9918035D0 (en) 1999-07-30 1999-07-30 Organic compounds
PCT/EP2000/007311 WO2001009134A1 (fr) 1999-07-30 2000-07-28 Inhibiteurs de derives de purine de la tyrosine kinase syk

Publications (1)

Publication Number Publication Date
IL147455A0 true IL147455A0 (en) 2002-08-14

Family

ID=10858317

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14745500A IL147455A0 (en) 1999-07-30 2000-07-28 Purine derivative inhibitors of tyrosine protein kinase syk

Country Status (33)

Country Link
US (1) US6589950B1 (fr)
EP (1) EP1200435B1 (fr)
JP (2) JP2003506375A (fr)
KR (1) KR100485289B1 (fr)
CN (1) CN1213047C (fr)
AR (1) AR029175A1 (fr)
AT (1) ATE251160T1 (fr)
AU (1) AU767349B2 (fr)
BR (1) BR0012888A (fr)
CA (1) CA2379560C (fr)
CO (1) CO5180626A1 (fr)
CZ (1) CZ2002299A3 (fr)
DE (1) DE60005684T2 (fr)
DK (1) DK1200435T3 (fr)
EC (1) ECSP003589A (fr)
ES (1) ES2208395T3 (fr)
GB (1) GB9918035D0 (fr)
HK (1) HK1046679A1 (fr)
HU (1) HUP0201935A3 (fr)
IL (1) IL147455A0 (fr)
MX (1) MXPA02001102A (fr)
MY (1) MY126862A (fr)
NO (1) NO20020467L (fr)
NZ (1) NZ516667A (fr)
PE (1) PE20010543A1 (fr)
PL (1) PL354477A1 (fr)
PT (1) PT1200435E (fr)
RU (1) RU2248977C2 (fr)
SK (1) SK285730B6 (fr)
TR (1) TR200200234T2 (fr)
TW (2) TWI274754B (fr)
WO (1) WO2001009134A1 (fr)
ZA (1) ZA200200783B (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040800A2 (fr) * 1999-11-30 2001-06-07 Parker Hughes Institute Syk localise au niveau du centrosome
FR2802091A1 (fr) * 1999-12-08 2001-06-15 Oreal Compositions pour la teinture des fibres keratiniques contenant des derives de paraphenylenediamine a groupement azetidinyle
AU2001293817A1 (en) 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
SI2311825T1 (sl) 2000-12-21 2016-02-29 Novartis Ag Pirimidinamini kot angiogenetski modulatorji
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
CA2463563A1 (fr) * 2001-10-12 2003-04-17 Irm Llc Squelettes d'inhibiteurs de kinase et leurs methodes de preparation
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
US20040014755A1 (en) 2002-01-10 2004-01-22 Dhanapalan Nagarathnam Rho-kinase inhibitors
US6924290B2 (en) 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
JP4423043B2 (ja) 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Ｒｈｏ−キナーゼ阻害剤
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
BR0307599A (pt) 2002-03-13 2005-02-01 Janssen Pharmaceutica Nv Derivados de sulfonilamino como inibidores de histona deacetilase
EA007272B1 (ru) 2002-03-13 2006-08-25 Янссен Фармацевтика Н. В. Новые ингибиторы гистондеацетилазы
US6897307B2 (en) 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
AU2003276125B2 (en) * 2002-06-17 2007-05-17 Smithkline Beecham Corporation Chemical process
AU2003256601B2 (en) * 2002-07-19 2009-10-29 Memory Pharmaceuticals Corporation 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
EP1444982A1 (fr) * 2003-02-06 2004-08-11 Merckle Gmbh Utilisation des dérivés de purine comme inhibiteurs sélectifs de kinases
CN1849318B (zh) 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
EP1656378A4 (fr) * 2003-08-15 2011-05-11 Irm Llc Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
US8026245B2 (en) * 2003-09-25 2011-09-27 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
CN1901903A (zh) * 2003-11-06 2007-01-24 细胞基因公司 用于治疗和控制石棉相关性疾病和病症的包含jnk抑制剂的组合物以及其使用方法
US7592177B2 (en) * 2003-11-10 2009-09-22 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
US8057815B2 (en) * 2004-04-19 2011-11-15 Portola Pharmaceuticals, Inc. Methods of treatment with Syk inhibitors
WO2005118543A1 (fr) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Inhibiteur des kinases et utilisation de cet inhibiteur
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
SG156685A1 (en) 2004-07-27 2009-11-26 Sgx Pharmaceuticals Inc Fused ring heterocycle kinase modulators
KR20070053237A (ko) * 2004-07-27 2007-05-23 에스지엑스 파마슈티컬스, 인코포레이티드 피롤로-피리딘 키나제 조절제
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
AU2005266312C1 (en) * 2004-07-28 2011-06-16 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
CA2579007A1 (fr) * 2004-09-10 2006-03-16 Altana Pharma Ag Combinaison de ciclesonide et d'inhibiteur de syk et procedes d'utilisation
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
CN100526315C (zh) * 2005-06-16 2009-08-12 浙江医药股份有限公司新昌制药厂 N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
AR056691A1 (es) * 2005-10-13 2007-10-17 Glaxo Group Ltd Derivados pirrolopirimidina como inhibidores de syk
CA2628474A1 (fr) * 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Modulateurs de kinase de type pyrimidinylthiophene
EP1960372B1 (fr) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Inhibiteurs de kinase et leurs utilisations
EP1979326B1 (fr) 2006-01-19 2012-10-03 Janssen Pharmaceutica N.V. Dérivés de pyridine et de pyrimidine en tant qu'inhibiteurs d'histone désacétylase
PL1981874T3 (pl) * 2006-01-19 2009-10-30 Janssen Pharmaceutica Nv Pochodne aminofenylowe jako nowe inhibitory deacetylazy histonowej
AU2007206950B2 (en) * 2006-01-19 2012-02-02 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
WO2007117465A2 (fr) * 2006-03-31 2007-10-18 Abbott Laboratories Composés d'indazole
KR20090071612A (ko) 2006-10-23 2009-07-01 에스지엑스 파마슈티컬스, 인코포레이티드 단백질 키나제 조정제로서의 바이시클릭 트리아졸
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EA019941B1 (ru) 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
WO2008081928A1 (fr) 2006-12-28 2008-07-10 Taisho Pharmaceutical Co., Ltd. Composé pyrazolopyridimidine
CA2683016A1 (fr) 2007-03-07 2008-09-12 Boehringer Ingelheim International Gmbh Nouveaux composes
US8242280B2 (en) 2007-04-10 2012-08-14 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN101289449A (zh) * 2007-04-20 2008-10-22 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和应用
WO2008135232A1 (fr) * 2007-05-02 2008-11-13 Riccardo Cortese Utilisation et compositions de dérivés de purine pour le traitement de troubles prolifératifs
JP2010528991A (ja) * 2007-05-21 2010-08-26 エスジーエックス ファーマシューティカルズ、インコーポレイテッド 複素環式キナーゼ調節因子
CL2008001540A1 (es) * 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
FR2929851B1 (fr) * 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
BRPI0910921B1 (pt) 2008-04-16 2022-06-21 Portola Pharmaceuticals, Inc Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2009131687A2 (fr) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibiteurs de protéines kinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
DK2300013T3 (en) 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010111406A2 (fr) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Composés et leurs utilisations thérapeutiques
CN102858767B (zh) * 2009-12-17 2015-08-19 默沙东公司 作为syk抑制剂的氨基嘧啶
PT2516434E (pt) * 2009-12-23 2015-10-05 Takeda Pharmaceutical Pirrolidinonas heteroaromáticas fundidas como inibidores de syk
WO2011153553A2 (fr) 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
CA2832504C (fr) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Composes permettant d'inhiber la proliferation cellulaire dans les cancers induits par l'egfr
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
CA2834604A1 (fr) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Aminopyrimidines en tant qu'inhibiteurs de syk
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
AU2012262021B2 (en) * 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2012177714A1 (fr) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Dérivés de 6-aza-isoindolin-1-one substitués
WO2013052391A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
EP2763975B1 (fr) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
EP2763976B1 (fr) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide
EA026939B1 (ru) 2011-11-23 2017-06-30 Портола Фармасьютикалз, Инк. Пиразиновые ингибиторы киназы
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
WO2013169401A1 (fr) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Composés pour inhiber la prolifération cellulaire dans les cancers induits par l'egfr
EP2863914B1 (fr) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
WO2013192128A1 (fr) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Analogues d'imidazolyle en tant qu'inhibiteurs de syk
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2013192088A1 (fr) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
EP2884982B1 (fr) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
WO2014048065A1 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Dérivés triazolyle en tant qu'inhibiteurs de la syk
WO2014093191A1 (fr) 2012-12-12 2014-06-19 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique contenant une aminopyridine
EP2934525B1 (fr) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Aminopyridines substituées par thiazole en tant qu'inhibiteurs de la tyrosine kinase de la rate
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP2988749B1 (fr) 2013-04-26 2019-08-14 Merck Sharp & Dohme Corp. Aminopyrimidines substituées par thiazole utilisées en tant qu'inhibiteurs de tyrosine kinase splénique
WO2014176210A1 (fr) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Composés aminohétéroaryle à substitution thiazole inhibiteurs de tyrosine kinase splénique
CN104418858B (zh) * 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
WO2015094997A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
US9868744B2 (en) 2014-04-25 2018-01-16 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
RU2570113C1 (ru) * 2014-12-08 2015-12-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук N-(2-ацетамидопурин-6-ил)глицин, обладающий противотуберкулезной активностью
CN107801397B (zh) * 2015-02-13 2021-07-30 达纳－法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
WO2017017571A1 (fr) * 2015-07-24 2017-02-02 Glaxo Group Limited Traitement du vitiligo
US10711002B2 (en) 2016-04-21 2020-07-14 The Royal Institution For The Advancement Of Learning/Mcgill University Purine compounds and method for the treatment of cancer
EP3528816A4 (fr) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
MX2020004155A (es) 2017-10-19 2020-08-03 Bayer Animal Health Gmbh Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.
WO2019241896A1 (fr) * 2018-06-22 2019-12-26 The Royal Institution For The Advancement Of Learning/Mcgill University Composés de purine et procédé pour letraitement du cancer
WO2020123675A1 (fr) * 2018-12-11 2020-06-18 Duke University Compositions et procédés pour le traitement du cancer
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US5583137A (en) 1992-02-19 1996-12-10 Pfizer Inc. Heterocyclic compounds for enhancing antitumor activity
JPH08502721A (ja) 1992-04-03 1996-03-26 ジ・アップジョン・カンパニー 医薬的に活性な二環式‐複素環アミン
US5550132A (en) 1994-06-22 1996-08-27 University Of North Carolina Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
EP0874846B1 (fr) * 1995-11-01 2003-04-02 Novartis AG Derives purines et procedes de preparation associes
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
AU735127B2 (en) * 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BR0012888A (pt) 2002-04-09
JP2003506375A (ja) 2003-02-18
KR20020015394A (ko) 2002-02-27
TR200200234T2 (tr) 2002-06-21
NZ516667A (en) 2004-05-28
DE60005684D1 (de) 2003-11-06
CA2379560A1 (fr) 2001-02-08
AU6567700A (en) 2001-02-19
PE20010543A1 (es) 2001-05-14
MY126862A (en) 2006-10-31
ATE251160T1 (de) 2003-10-15
WO2001009134A1 (fr) 2001-02-08
MXPA02001102A (es) 2002-08-20
HUP0201935A2 (hu) 2002-11-28
SK1262002A3 (en) 2002-07-02
TWI255268B (en) 2006-05-21
HUP0201935A3 (en) 2005-02-28
NO20020467D0 (no) 2002-01-29
PL354477A1 (en) 2004-01-26
CA2379560C (fr) 2009-09-29
ECSP003589A (es) 2002-02-25
AU767349B2 (en) 2003-11-06
AR029175A1 (es) 2003-06-18
GB9918035D0 (en) 1999-09-29
KR100485289B1 (ko) 2005-04-27
ES2208395T3 (es) 2004-06-16
HK1046679A1 (zh) 2003-01-24
NO20020467L (no) 2002-03-20
ZA200200783B (en) 2003-04-30
SK285730B6 (sk) 2007-07-06
DE60005684T2 (de) 2004-07-29
DK1200435T3 (da) 2004-02-02
CN1213047C (zh) 2005-08-03
EP1200435A1 (fr) 2002-05-02
JP2007217426A (ja) 2007-08-30
PT1200435E (pt) 2004-02-27
EP1200435B1 (fr) 2003-10-01
CZ2002299A3 (cs) 2002-04-17
CO5180626A1 (es) 2002-07-30
TWI274754B (en) 2007-03-01
US6589950B1 (en) 2003-07-08
TW200524932A (en) 2005-08-01
RU2248977C2 (ru) 2005-03-27
CN1365360A (zh) 2002-08-21

Similar Documents

Publication Publication Date Title
IL147455A0 (en) Purine derivative inhibitors of tyrosine protein kinase syk
HUS1700048I1 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
HK1244797A1 (zh) 環蛋白酪氨酸激酶抑制劑
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
IL182428A0 (en) Indolylmaleimide derivatives as protein kinase c inhibitors
EG24381A (en) Tyrosine kinase inhibitors
IL137041A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HK1035188A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
EP1161433A4 (fr) Inhibiteurs de tyrosine kinase
HK1049154A1 (zh) 作為酪氨酸激酶抑制劑的2-吡唑啉-5-酮
IL127796A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU2563900A (en) Quinoline derivatives as tyrosine kinase inhibitors
AU1371999A (en) Benzothiazole protein tyrosine kinase inhibitors
AU8689298A (en) Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
GB9613021D0 (en) Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
GB9524131D0 (en) Pyrido-pyrimidine compounds as tyrosine kinase inhibitors